827-32-7

Basic information

• Product Name: 4-bromo-5-methyl-2-nitroaniline
• Synonyms: 4-bromo-5-methyl-2-nitroaniline;4-broMo-5-Methyl-2-nitrobenzenaMine;BenzenaMine, 4-broMo-5-Methyl-2-nitro-;4-Bromo-5-methyl-2-nitro-phenylamine
• CAS NO: 827-32-7
• Molecular Formula: C₇H₇BrN₂O₂
• Molecular Weight: 231.05
• Mol File: 827-32-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 335.231 °C at 760 mmHg
• Flash Point: 156.542 °C
• Appearance: /
• Density: 1.689
• PKA: -0.80±0.25(Predicted)
• CAS DataBase Reference: 4-bromo-5-methyl-2-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-5-methyl-2-nitroaniline(827-32-7)
• EPA Substance Registry System: 4-bromo-5-methyl-2-nitroaniline(827-32-7)

Safety Data

• Hazardous Substances Data: 827-32-7(Hazardous Substances Data)

Usage

General Description

4-Bromo-5-methyl-2-nitroaniline is a chemical compound with the molecular formula C7H7BrN2O2. It is a yellow crystalline solid that is commonly used as an intermediate in the synthesis of various organic compounds, especially dyes and pharmaceuticals. 4-Bromo-5-methyl-2-nitroaniline is classified as a substituted aniline, meaning it is a derivative of aniline with substitutions at the 4-bromo, 5-methyl, and 2-nitro positions. It is known to be a mild to moderate skin irritant and may cause eye irritation upon contact. Additionally, 4-Bromo-5-methyl-2-nitroaniline is considered to be toxic if ingested, inhaled, or absorbed through the skin, and the appropriate safety precautions should be followed when handling this chemical.

Upstream product

• 90914-81-1 4-bromo-3-methylacetanilide 
• 578-46-1 5-methyl-2-nitroaniline 
• 716-65-4 N-(4-bromo-5-methyl-2-nitrophenyl)acetamide 

Downstream Products

• 885270-77-9 3-N-(tert-butoxycarbonyl)-3,4-diaminotoluene 
• 1225279-36-6 6-methyl-7-[3-(piperidin-1-ylmethyl)phenyl]quinoxaline 
• 102169-44-8 4-bromo-5-methyl-1,2-o-phenylenediamine 
• 1052686-64-2 5-methyl-4-(pyridin-3-yl)-2-nitroaniline 
• 10300-82-0 4-Bromo-5-methyl-2-nitro-N-D-ribitylaniline 
• 392318-87-5 2,6-dibromo-3,5-dinitro-toluene 
• 101581-06-0 1,3-dibromo-2-methyl-5-nitrobenzene 
• 140373-62-2 2,5-dibromo-4-methyl-aniline 
• 69321-60-4 2,6-dibromotoluene 
• 13194-73-5 3,5-dibromo-4-methylaniline 
• 7745-91-7 3-bromo-4-methylaniline 

Relevant articles and documents

KINASE INHIBITORS AND USES THEREOF

Provided are cyclic iminopyridimdine compounds and their bicyclic derivatives, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to kinases such as MAPK, PDGFR, Src, PAKs, c-Kit, EphA2, EphB4, FGFR, Axl, and c-Met.

FUSED PYRAZINE DERIVATIVES AS KINASE INHIBITORS

A series of quinoxaline derivatives, and analogues thereof, which are functionalised further by a substituted phenyl or pyridinyl moiety, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Crystal packing: An examination of the packing of molecules approximately isosteric with 4,5-dichlorophthalic anhydride

The crystal structures of five 5,6-disubstituted benzofurazan 1-oxides are presented and compared with five previously reported structures: three polymorphs of 5,6-dichlorobenzofurazan 1-oxide plus 4,5-dichloro- and 4,5-dibromophthalic anhydride. All but one of these compounds pack with similar two-dimensional layers. The benzofurazan oxides all show disorder about a crystallographic twofold or pseudo-twofold axis. In addition, six complexes of phthalic anhydride and benzofurazan oxides are reported. With the packing in the complexes principally directed by the π complexing, the disorder, invariably found in the uncomplexed benzofurazan oxides, is diminished, and, in two cases, eliminated.